Note |
The WHO criteria include 1) stable increase in peripheral blood monocyte count (> 1 x 109/L); 2) lack of Philadelphia chromosome and BCR-ABL fusion gene; 3) lack of gene rearrangement involving the Platelet-Derived Growth Factor Receptor Beta gene (PDGFRB); 4) blast cell percentage in the blood and the bone marrow lower than 20% and 5) cellular dysplasia of at least one myeloid cell line. This last criterion is not mandatory, as monocyte dysplasia can be difficult to assess in the bone marrow, and dysplasia of other lineages is inconstant. Thus, CMML may not always have a cytologically identifiable dysplastic component. When dysplasia is missing, diagnosis can be made if a clonal cytogenetic or molecular abnormality is identified in hematopoietic cells, or if peripheral blood monocyte count remains elevated at least 3 months without any other explanation. |
Phenotype / cell stem origin |
The cell of origin is a multipotential stem cell. |
Epidemiology | CMML is a relatively rare disease whose incidence is around 1 case/100000 inhabitants per year. CMML is a disease of older adults, with a strong male predominance. The median age at diagnosis is around 70 years, the disease is exceptionally diagnosed before 50 years of age. |
Clinics | The onset of the disease is usually insidious and, diagnosis is fortuitous in many cases. Symptoms, when present, are the consequences of cytopenias (notably anemia, which is invalidating in a third of patients), and/or of extramedullary hematopoiesis, notably splenomegaly but also hepatomegaly, skin infiltration, gum infiltration, and serous (notably pleural) effusions. Extramedullary hematopoiesis is mostly restricted to patients with WBC > 13 G/L. Finally, auto-immune manifestations (seronegative arthritis, vasculitis) can be associated to CMML. |
Cytology | Peripheral blood count indicates monocytosis (up to 80 x 109/L). Cells identified by cytologists as monocytes are heterogeneous, commonly including mature monocytes, dysplastic monocytes, and a variable fraction of dysplastic granulocytes (these cells do not express CD14 but express granulocytic markers CD15 and CD24, belong to the leukemic clone, and demonstrate immunosuppressive properties like myeloid-derived suppressive cells). An increase in neutrophils or eosinophils can be associated, as well as myelemia. Anemia is usually moderate, normocytic or macrocytic. Thrombocytopenia is inconstant and can be severe. Of note, an immune mechanism can contribute to these cytopenias. Hyperuricemia, increased B12 plasma level, increase serum and urine lysozyme, and polyclonal hypergammaglobulinemia can be observed. Bone marrow: Bone marrow smears show a hypercellular tissue in which blast cell percentage (myeloblasts and monoblasts) remains lower than 20%. Monocyte proliferation is always present and often moderate (10 to 15% of mononuclear cells) and dysplastic changes can be observed in one or several lineages. A variable degree of myelofibrosis can be detected in up to 30% of patients. |
Treatment | Allogeneic stem cell transplantation remains the only potentially curative option but is rarely feasible, due to the age of patients. In those ineligible for transplantation, the mainstay of CMML treatment is hydroxyurea, which is usually initiated when the disease becomes proliferative. The overall response rate reaches 60% but complete response is exceptional. The hypomethylating agent azacitidine (AZA) has been approved in Europe for CMML with WBC < 13 G/L and bone marrow blasts between 10 and 29%. The other hypomethylating agent, decitabine, is approved in US, not in Europe. An overall response rate of 40% is observed with these drugs. Prospective randomized comparisons of hypomethylating agents versus hydrxyurea have still to be performed. |
Prognosis | The median survival for patients with CMML is 24-36 months. According to the WHO, the main prognostic factor is the percentage of blast cells in the blood and the bone marrow. Several prognostic scores have been proposed that rely on peripheral blood counts, serum lactate deshydrogenase values, and percentage of bone marrow blast cells and cytogenetic abnormalities. More recent data suggest that cytogenetic and molecular information could be prognostically useful. Cytogenetics is part of a recent Spanish score whereas a recent French prognostic score includes the presence of mutations in ASXL1 gene, which is an independent poor prognostic factor in CMML. An international staging system may be established in the coming years. |
Transcription intermediary factor 1 gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. |
Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L. |
J Clin Invest. 2011 Jun;121(6):2361-70. doi: 10.1172/JCI45213. Epub 2011 May 2. |
PMID 21537084 |
|
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. |
Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, Meurice G, Orear C, Preudhomme C, Gardin C, Ades L, Fontenay M, Fenaux P, Droin N, Solary E; Groupe Francophone des Myelodysplasies. |
Blood. 2011 Oct 6;118(14):3824-31. doi: 10.1182/blood-2011-05-352039. Epub 2011 Aug 9. |
PMID 21828134 |
|
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. |
Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, Gelsi-Boyer V, de Botton S, Vey N, Preudhomme C, Clavert A, Delabesse E, Park S, Birnbaum D, Fontenay M, Bernard OA, Solary E. |
Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5. |
PMID 23443343 |
|
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. |
Droin N, Jacquel A, Hendra JB, Racoeur C, Truntzer C, Pecqueur D, Benikhlef N, Ciudad M, Guery L, Jooste V, Dufour E, Fenaux P, Quesnel B, Kosmider O, Fontenay M, Ducoroy P, Solary E. |
Blood. 2010 Jan 7;115(1):78-88. doi: 10.1182/blood-2009-05-224352. Epub 2009 Oct 28. |
PMID 19864642 |
|
An evolutionary perspective on chronic myelomonocytic leukemia. |
Itzykson R, Solary E. |
Leukemia. 2013 Jul;27(7):1441-50. doi: 10.1038/leu.2013.100. Epub 2013 Apr 5. (REVIEW) |
PMID 23558522 |
|
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. |
Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. |
Blood. 2011 Oct 6;118(14):3932-41. doi: 10.1182/blood-2010-10-311019. Epub 2011 Aug 9. |
PMID 21828135 |
|
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. |
Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I. |
Nature. 2011 May 12;473(7346):230-3. doi: 10.1038/nature09999. |
PMID 21562564 |
|
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. |
Kosmider O, Itzykson R, Chesnais V, Lasho T, Laborde R, Knudson R, Gauthier A, Merlevede J, Ades L, Morabito M, Fontenay M, Tefferi A, Droin N, Solary E. |
Leukemia. 2013 Sep;27(9):1946-9. doi: 10.1038/leu.2013.182. Epub 2013 Jun 18. |
PMID 23774674 |
|
Importance of genetics in the clinical management of chronic myelomonocytic leukemia. |
Padron E, Abdel-Wahab O. |
J Clin Oncol. 2013 Jul 1;31(19):2374-6. doi: 10.1200/JCO.2013.48.9120. Epub 2013 May 20. |
PMID 23690427 |
|
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. |
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. |
Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30. |
PMID 23632888 |
|
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. |
Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luno E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G. |
Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31. |
PMID 23372164 |
|